Trials / Terminated
TerminatedNCT02973269
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | daxibotulinumtoxin type A | Intramuscular injection |
| BIOLOGICAL | Placebo | Intramuscular injection |
Timeline
- Start date
- 2016-11-14
- Primary completion
- 2017-05-31
- Completion
- 2017-05-31
- First posted
- 2016-11-25
- Last updated
- 2024-04-03
- Results posted
- 2024-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02973269. Inclusion in this directory is not an endorsement.